PT - JOURNAL ARTICLE AU - Pope, Bernard J. AU - Clendenning, Mark AU - Rosty, Christophe AU - Mahmood, Khalid AU - Georgeson, Peter AU - Joo, Jihoon E. AU - Walker, Romy AU - Hutchinson, Ryan A. AU - Jayasekara, Harindra AU - Joseland, Sharelle AU - Como, Julia AU - Preston, Susan AU - Spurdle, Amanda B. AU - Macrae, Finlay A. AU - Win, Aung K. AU - Hopper, John L. AU - Jenkins, Mark A. AU - Winship, Ingrid M. AU - Buchanan, Daniel D. TI - Germline and Tumor Whole Genome Sequencing as a Diagnostic Tool to Resolve Suspected Lynch Syndrome AID - 10.1101/2020.03.12.20034991 DP - 2020 Jan 01 TA - medRxiv PG - 2020.03.12.20034991 4099 - http://medrxiv.org/content/early/2020/03/17/2020.03.12.20034991.short 4100 - http://medrxiv.org/content/early/2020/03/17/2020.03.12.20034991.full AB - Background People who develop mismatch repair (MMR) deficient cancer in the absence of a germline MMR gene pathogenic variant or hypermethylation of the MLH1 gene promoter in their tumor are classified as having suspected Lynch syndrome (SLS). We applied germline whole genome sequencing (WGS) and targeted and genome-wide tumor sequencing approaches to identify the underlying cause of tumor MMR-deficiency in SLS.Methods Germline WGS was performed on 14 cancer-affected people with SLS, including two sets of first-degree relatives. Tumor tissue was sequenced for somatic MMR gene mutations by targeted, whole exome sequencing or WGS. Germline pathogenic variants, including complex structural rearrangements and non-coding variants, were assessed for the MMR genes. Tumor mutation burden and mutational signatures.Results Germline WGS identified pathogenic MMR variants in 3 of the 14 (21.4%) SLS cases including a 9.5Mb inversion disrupting exons 1-7 of MSH2 in a mother and daughter. Excluding these 3 MMR carriers, tumor sequencing identified at least two somatic MMR gene mutations in 8/11 (72.7%) tumors tested, supporting a non-inherited cause of tumor MMR-deficiency. In the second mother-daughter pair, the combined analysis of germline and tumor by WGS supported a somatic rather than inherited cause of their tumor MMR-deficiency, through presence of double somatic MSH2 mutations in their respective tumors.Conclusion Germline WGS of people with SLS improved the identification of Lynch syndrome. When coupled with tumor sequencing, >70% of the people with SLS were resolved as having double somatic MMR mutations and a non-inherited cause for their tumor MMR-deficiency.Competing Interest StatementDr Buchanan served as a consultant on the Tumor Agnostic (dMMR) Advisory Board of Merck Sharp and Dohme in 2017 and 2018 for Pembrolizumab.Funding StatementFunding by a National Health and Medical Research Council of Australia (NHMRC) project grant 1125269 (PI- Daniel Buchanan), supported the design, analysis and interpretation of data. DDB is supported by a NHMRC R.D. Wright Career Development Fellowship and funding from the University of Melbourne Research at Melbourne Accelerator Program (R@MAP). BJP is supported by a Victorian Health and Medical Research Fellowship from the Department of Health and Human Services in the State of Victoria. PG is supported by an Australian Government Research Training Program Scholarship. ABS was supported by an NHMRC Senior Research Fellowship (ID1061779). “Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number UM1CA167551 and through cooperative agreements with the following CCFR centers: Australasian Colorectal Cancer Family Registry (NCI/NIH U01 CA074778 and U01/U24 CA097735) and by the Victorian Cancer Registry, Australia. This research was performed under CCFR approved project C-AU-1014-01.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon request>AbbreviationsWGS(whole genome sequencing)WES(whole exome sequencing)MMR(mismatch repair)IHC(immunohistochemical)MSI(microsatellite instability)VCF(variant call format)LS(Lynch syndrome)SLS(suspected Lynch Syndrome)CRC(colorectal cancer)EC(endometrial cancer)MLPA(multiplex ligation-dependent PCR amplification)SV(structural variant)SNV(single nucleotide polymorphism)INDEL(insertion or deletion)PCR(polymerase chain reaction)HTS(High Throughput Sequencing)VAF(variant allele fraction)ACCFR(Australasian Colorectal Cancer Family Registry).